By Josh Beckerman

Shares of Synergy Pharmaceuticals Inc. (SGYP), which filed for bankruptcy last week, recently traded up 55% to 12 cents as the company's flagship product Trulance was accepted for review by Health Canada.

Cipher Pharmaceuticals Inc. (CPH.T) bought Canadian rights to the constipation drug in Februrary.

Synergy filed for chapter 11 on Dec. 12 with a plan to sell its assets to Bausch Health Companies Inc. (BHC) for about $200 million in cash.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

December 17, 2018 15:28 ET (20:28 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Grafico Azioni Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Synergy Pharmaceuticals, Inc.
Grafico Azioni Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Synergy Pharmaceuticals, Inc.